Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,dividendsPaid,capitalExpenditures,changeToNetincome,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 12, 2018) 4","Short Ratio (Jul 12, 2018) 4","Short % of Float (Jul 12, 2018) 4","Short % of Shares Outstanding (Jul 12, 2018) 4","Shares Short (prior month Jun 14, 2018) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,IMNPQ,-4313000.0,172878000,2054000,,-4132000,,-4132000,1644000,0,-3698000,-3698000,,-498000,,,,0,0,3698000,0,-434000,,-4132000,-9673000,5155000.0,127607000.0,19874000.0,842000.0,15000000.0,186000.0,20716000.0,4000.0,288000.0,-126769000.0,4142000.0,15100000.0,76000.0,14862000.0,3685000.0,97000.0,364000.0,870000.0,5535000.0,1938000.0,-38000.0,100000.0,101000.0,-8000.0,3000.0,-1432000.0,-1495000.0,209000.0,-2000.0,-38000.0,,,-14498000.0,en-US,US,EQUITY,False,Delayed Quote,USD,IMMUNE PHARMACEUTICALS INC,-0.87315285,1776197,0.15263158,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0029,1630511020,0.00040000002,0.0019,0.0033,0.0019,290000,PNK,us_market,16.000002,0.0019 - 0.0033,0.0025,0.0,0.0,0,0,finmb_112205409,Other OTC,"Immune Pharmaceuticals, Inc.",USD,224971,167567,0.0027,13.500001,2.0E-4 - 0.179,-0.1761,-0.98379886,0.0002,0.179,1492041600,1542211140,1568890740,1568980800,-1.147,0.019,0.0026,0.00029999996,0.1153846,0.022862168,-0.019962167,2.06,,,0.179,0.0002,0.0026,0.0229,224.97k,167.57k,172.88M,,46.26M,6.52%,0.00%,1.08M,1.32,3.03%,3.00%,865.08k,,,,,,0.00%,"Apr 12, 2017",,1:20,"Apr 12, 2017","Dec 30, 2017","Sep 29, 2018",0.00%,0.00%,-42.63%,"-2,315.48%",,,,,-13.77M,-34.39M,-1.1470,,76k,0,8.33M,989.55,0.02,0.02,-14.69M,-7.46M,Value,07024,Healthcare,7,"Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",Fort Lee,201-464-2677,NJ,1546214400,United States,http://www.immunepharma.com,86400,1 Bridge Plaza North,Biotechnology,Suite 270
t-1,IMNPQ,-706000.0,172878000,1715000,,-4717000,,-4717000,1128000,0,-2843000,-2843000,,-281000,,,,0,0,2843000,0,-1874000,,-4717000,-10316000,5363000.0,127290000.0,17605000.0,4657000.0,15000000.0,540000.0,22262000.0,4000.0,230000.0,-122637000.0,4142000.0,15100000.0,1508000.0,12593000.0,3620000.0,61000.0,1738000.0,870000.0,3597000.0,-86000.0,-30000.0,2007000.0,1961000.0,-479000.0,3000.0,-1226000.0,-3157000.0,231000.0,-46000.0,-30000.0,1612000.0,,-10855000.0,en-US,US,EQUITY,False,Delayed Quote,USD,IMMUNE PHARMACEUTICALS INC,-0.87315285,1776197,0.15263158,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0029,1630511020,0.00040000002,0.0019,0.0033,0.0019,290000,PNK,us_market,16.000002,0.0019 - 0.0033,0.0025,0.0,0.0,0,0,finmb_112205409,Other OTC,"Immune Pharmaceuticals, Inc.",USD,224971,167567,0.0027,13.500001,2.0E-4 - 0.179,-0.1761,-0.98379886,0.0002,0.179,1492041600,1542211140,1568890740,1568980800,-1.147,0.019,0.0026,0.00029999996,0.1153846,0.022862168,-0.019962167,2.06,,,0.179,0.0002,0.0026,0.0229,224.97k,167.57k,172.88M,,46.26M,6.52%,0.00%,1.08M,1.32,3.03%,3.00%,865.08k,,,,,,0.00%,"Apr 12, 2017",,1:20,"Apr 12, 2017","Dec 30, 2017","Sep 29, 2018",0.00%,0.00%,-42.63%,"-2,315.48%",,,,,-13.77M,-34.39M,-1.1470,,76k,0,8.33M,989.55,0.02,0.02,-14.69M,-7.46M,Value,07024,Healthcare,7,"Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",Fort Lee,201-464-2677,NJ,1546214400,United States,http://www.immunepharma.com,86400,1 Bridge Plaza North,Biotechnology,Suite 270
t-2,IMNPQ,3108000.0,172878000,2394000,,-4384000,,-4384000,1932000,0,-4326000,-4326000,,-65000,,,,0,0,4326000,0,-58000,,-4384000,-4384000,6247000.0,127272000.0,14972000.0,9355000.0,15000000.0,516000.0,24327000.0,3000.0,215000.0,-117920000.0,4142000.0,15100000.0,2734000.0,9396000.0,3172000.0,31000.0,2949000.0,1434000.0,3683000.0,114000.0,-31000.0,-205000.0,-319000.0,189000.0,3000.0,-4042000.0,-3692000.0,230000.0,-114000.0,-31000.0,94000.0,,-6447000.0,en-US,US,EQUITY,False,Delayed Quote,USD,IMMUNE PHARMACEUTICALS INC,-0.87315285,1776197,0.15263158,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0029,1630511020,0.00040000002,0.0019,0.0033,0.0019,290000,PNK,us_market,16.000002,0.0019 - 0.0033,0.0025,0.0,0.0,0,0,finmb_112205409,Other OTC,"Immune Pharmaceuticals, Inc.",USD,224971,167567,0.0027,13.500001,2.0E-4 - 0.179,-0.1761,-0.98379886,0.0002,0.179,1492041600,1542211140,1568890740,1568980800,-1.147,0.019,0.0026,0.00029999996,0.1153846,0.022862168,-0.019962167,2.06,,,0.179,0.0002,0.0026,0.0229,224.97k,167.57k,172.88M,,46.26M,6.52%,0.00%,1.08M,1.32,3.03%,3.00%,865.08k,,,,,,0.00%,"Apr 12, 2017",,1:20,"Apr 12, 2017","Dec 30, 2017","Sep 29, 2018",0.00%,0.00%,-42.63%,"-2,315.48%",,,,,-13.77M,-34.39M,-1.1470,,76k,0,8.33M,989.55,0.02,0.02,-14.69M,-7.46M,Value,07024,Healthcare,7,"Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",Fort Lee,201-464-2677,NJ,1546214400,United States,http://www.immunepharma.com,86400,1 Bridge Plaza North,Biotechnology,Suite 270
t-3,IMNPQ,7281000.0,172878000,1843000,,-5122000,,-3149000,1962000,0,-3805000,-3805000,,-65000,,,,-1973000,0,3805000,0,-1317000,,-3149000,-10013000,6477000.0,127292000.0,14850000.0,13758000.0,15000000.0,482000.0,28608000.0,2000.0,255000.0,-113536000.0,4142000.0,15100000.0,6776000.0,9251000.0,3296000.0,,7031000.0,1457000.0,3569000.0,-4836000.0,-6000.0,-2980000.0,13048000.0,-378000.0,3000.0,6700000.0,-6342000.0,230000.0,-16000.0,-6000.0,1207000.0,7355000.0,-2220000.0,en-US,US,EQUITY,False,Delayed Quote,USD,IMMUNE PHARMACEUTICALS INC,-0.87315285,1776197,0.15263158,15,America/New_York,EDT,-14400000,False,False,PRE,0,4,0.0029,1630511020,0.00040000002,0.0019,0.0033,0.0019,290000,PNK,us_market,16.000002,0.0019 - 0.0033,0.0025,0.0,0.0,0,0,finmb_112205409,Other OTC,"Immune Pharmaceuticals, Inc.",USD,224971,167567,0.0027,13.500001,2.0E-4 - 0.179,-0.1761,-0.98379886,0.0002,0.179,1492041600,1542211140,1568890740,1568980800,-1.147,0.019,0.0026,0.00029999996,0.1153846,0.022862168,-0.019962167,2.06,,,0.179,0.0002,0.0026,0.0229,224.97k,167.57k,172.88M,,46.26M,6.52%,0.00%,1.08M,1.32,3.03%,3.00%,865.08k,,,,,,0.00%,"Apr 12, 2017",,1:20,"Apr 12, 2017","Dec 30, 2017","Sep 29, 2018",0.00%,0.00%,-42.63%,"-2,315.48%",,,,,-13.77M,-34.39M,-1.1470,,76k,0,8.33M,989.55,0.02,0.02,-14.69M,-7.46M,Value,07024,Healthcare,7,"Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is based in Fort Lee, New Jersey. On April 2, 2020, the voluntary petition of Immune Pharmaceuticals, Inc. along with its affiliates, for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on February 17, 2020.",Fort Lee,201-464-2677,NJ,1546214400,United States,http://www.immunepharma.com,86400,1 Bridge Plaza North,Biotechnology,Suite 270
